NICE rejects Roche's Tecentriq in new lung cancer use

NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d

The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

An alternative set of metrics for the UK’s pricing and acces...

Leela Barham takes a look at alternative ways pharma and the UK government could measure progress for the VPAS.

UK's NHS to fund Shionogi's Mulpleo after backing from NICE ...

Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

NHS patients to get easier access to MS pill after NICE reth...

Patients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription.